ZIONS BANCORPORATION, NATIONAL ASSOCIATION /UT/ (Form: 8-K, Received: 11/30/2020 08:29:24)
false000010938000001093802020-11-302020-11-3000001093802020-10-282020-10-280000109380exch:XNASus-gaap:CommonStockMember2020-11-302020-11-300000109380exch:XNASzions:SeriesAFloatingRateNonCumulativePerpetualPreferredStockMember2020-11-302020-11-300000109380exch:XNASzions:SeriesGFixedFloatingRateNonCumulativePerpetualPreferredStockMember2020-11-302020-11-300000109380exch:XNASzions:SeriesH575NonCumulativePerpetualPreferredStockMember2020-11-302020-11-300000109380zions:FixedToFloating695RateSubordinatedNotesDueSeptember142028Memberexch:XNAS2020-11-302020-11-30




UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) November 30, 2020
ZIONS BANCORPORATION, NATIONAL ASSOCIATION
(Exact name of registrant as specified in its charter)


United States of America 001-12307 87-0189025
(State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.)

One South Main, Salt Lake City, Utah 84133
        (Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code (801) 844-7637

(Former name or former address, if changed since last report.)
Securities registered pursuant to Section 12(b) of the Act:
Title of Each Class Trading Symbol Name of Each Exchange on Which Registered
Common Stock, par value $0.001
ZION The NASDAQ Stock Market, LLC
Depositary Shares each representing a 1/40th ownership interest in a share of:
Series A Floating-Rate Non-Cumulative Perpetual Preferred Stock
ZIONP
The NASDAQ Stock Market, LLC
Series G Fixed/Floating-Rate Non-Cumulative Perpetual Preferred Stock
ZIONO
The NASDAQ Stock Market, LLC
Series H 5.75% Non-Cumulative Perpetual Preferred Stock
ZIONN
The NASDAQ Stock Market, LLC
6.95% Fixed-to-Floating Rate Subordinated Notes due September 15, 2028
ZIONL
The NASDAQ Stock Market, LLC

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange act. ¨






Item 8.01 Other Events.

On Monday, November 30, 2020, Harris Simmons, Chairman and Chief Executive Officer of Zions Bancorporation, N.A. (Zions), issued a letter to the Zions Board of Directors, employees and colleagues regarding a recently diagnosed medical condition. A copy of his letter is attached as Exhibit 99.1.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

99.1 Letter of Harris H. Simmons, Chairman and Chief Executive Officer of Zions Bancorporation, N.A.

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: November 30, 2020 ZIONS BANCORPORATION, NATIONAL ASSOCIATION
(Registrant)
By: /s/ Thomas E. Laursen
Name: Thomas E. Laursen
Title: Executive Vice President & General Counsel


Exhibit 99.1

Dear Colleagues:

I hope you all had a wonderful Thanksgiving. My own Thanksgiving was especially notable, as I’ve gained a profound appreciation for some of the rapid advances being made in medicine in recent years.

On Veteran’s Day, November 11, I went in for a routine colonoscopy. The following day, I received a call from my doctor indicating that biopsies taken during the procedure indicated the presence of lymphoma, a non-hereditary form of cancer of the lymph system. I immediately made an appointment with an oncologist who informed me that the pathology report on the biopsies indicated the presence of a relatively rare form of non-Hodgkin’s lymphoma known as Mantle Cell Lymphoma. Until quite recently, Mantle Cell Lymphoma was essentially incurable, but enormous advances have been made over the past few years, and as recently as July of this year the FDA approved a gene therapy involving the use of a patient’s own T-cells which has shown to be highly effective in eradicating the cancerous cells and in a solid majority of cases producing complete remission even in patients who have relapsed or who are no longer responding to more established treatments.

In my quick research regarding Mantle Cell Lymphoma, I found that much of the literature is dated and offers a pretty gloomy prognosis. But I also learned that Dr. Michael Wang, who heads the Mantle Cell Lymphoma program at Houston’s MD Anderson Cancer Center—one of the premier cancer research hospitals in the world—is arguably the leading expert on this form of lymphoma, and that he also conducted the recent and very successful T-cell therapy trial which led to FDA approval for treatment. A week after my initial diagnosis—this past Monday—I met with Dr. Wang, and he told me he felt confident that I’m going to live a very long time. On Thanksgiving Day, I began the non-chemo targeted therapy treatments that are the initial protocol for battling this disease. It is not uncommon for this phase, which is not a cure, to eventually lead to relapse, which is then treated with the T-cell gene therapy that has shown great promise as a “knock-out” punch for this type of cancer.

I’m highly optimistic and upbeat about what my future holds. I expect to live for many additional years, and to be fully productive for a long time to come. But my schedule, particularly over the next two or three months, may be disrupted somewhat as I’ll be needing to attend to these medical needs, including frequent travel to Houston to meet with my doctors there. I take great comfort in the fact that we have a strong management team who can capably carry on during any of my brief absences. I’ve communicated this plan to our Board of Directors, and I’m very grateful for their full support.

This is a time of year when our thoughts tend toward the people and the things for which we’re most grateful. In my case, that includes my wife, Amanda, and my four great kids, and my extended family; my faith; the exceptional scientists and healthcare professionals and their teams who are making such amazing advances in treating once



intractable diseases; and the great many friends and colleagues I have, including all of you whom I have the singular privilege of working with. I deeply appreciate your prayers and support.

Sincerely,

Harris H. Simmons
Chairman and CEO



SEC Filings provided by EDGAR Online, Inc.